EyePoint Pharmaceuticals Reports $59.7M Loss
Update: 2025-11-05
Description
EyePoint Pharmaceuticals reports a significant third-quarter loss, with a net loss of $59.7 million, or $0.85 per share, falling short of analysts' expectations of $0.77 per share. Despite the loss, the company's revenue stood at $966,000, and they remain committed to their drug delivery technology research and development.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
